DREAMM20

A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

Published Results

Belantamab Monotherapy Demonstrates Safety and Durable Responses for Heavily Pretreated R/R MM: Results From DREAMM-20

In this open-label dose-escalation study, 18 patients with ≥3 prior lines of therapy (94% triple-class exposed) were treated with belantamab monotherapy IV every 2 weeks at doses of 300 mg, 900 mg, or 2000 mg (n = 6 per cohort). The median age was 76 years (range, 42 to 86), and 2 patients had received prior BCMA-directed therapy.

The median duration of exposure was 63.5 days, and no dose-limiting toxicities or adverse reactions led to treatment discontinuation. The most common treatment-related adverse events were infusion reactions (22%) and hematologic events. The most common grade 3 or higher adverse events were neutrophil count decrease (22%) and anemia (17%).

The overall response rate (ORR) was 28%, including 2 very good partial responses and 3 partial responses. Disease was observed in another five patients (28%).

1 month agoRead more

Resources

(888) 850-0650

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.